Skip to main content
. 2016 Jun 7;7(31):49349–49367. doi: 10.18632/oncotarget.9885

Figure 2. Ca-TAT delivery of CCL2 siRNAs inhibits growth and enhances cell death of primary MDA-MB-231 tumor xenografts.

Figure 2

A. Experimental plan for treatment of MDA-MB-231 tumor bearing mice with Ca-TAT/siRNA complexes. 21 days post transplantation, tumors received injections every three days with Ca-TAT peptides complexed to 10 micrograms control or CCL2 siRNAs (huCCL2si1, huCCL2si2) for a total of three injections, n=6 per group. Animals were euthanized 30 days post-transplantation for tissue harvest and analysis. B. Tumor and surrounding normal mammary tissues were analyzed for CCL2 expression by flow cytometry C. Representative tumors with quantified tumor mass. D. Representative H&E stain of primary tumor xenografts. Necrotic areas were identified on H&E stains at 5 different depths of the tumor and quantified by Image J analysis. Necrotic areas are outlined. Scale bar= 200 microns. Statistical analysis was performed by One way ANOVA followed by Bonferonni post-hoc comparisons with Control siRNA group. Statistical significance was determined by p-value less than 0.05. **p<0.01, ***p<0.001, n.s= not significant. Mean+SEM is shown.